Source link : https://www.newshealth.biz/health-news/durable-responses-seen-with-barzolvolimab-in-csu-trial/
AMSTERDAM — Patients with chronic spontaneous urticaria (CSU) experienced early and sustained improvements in symptom scores on treatment with barzolvolimab, during the 52-week follow-up of an ongoing phase 2 study. Moreover, in the study, barzolvolimab, an anti-KIT monoclonal antibody that inhibits the activation of and depletes mast cells, induced comparable responses in a subset of […]
Author : News Health
Publish date : 2024-10-01 12:10:57
Copyright for syndicated content belongs to the linked Source.
Categories